Sastasundar Ventures Ltd Q2 FY26 – Flipkart Exit, ₹600 Crore RPTs, and a Digital Healthcare Circus

1. At a Glance

Ladies and gentlemen, welcome to the great Indian healthcare bazaar — Sastasundar Ventures Ltd (SSVL) — where digital health, diagnostics, and financial services all live under one confused corporate roof.

As of November 2025, the ₹1,014 crore market-cap company is trading around ₹317 per share, up 16.4% in the past 3 months. Despite the “Sasta” in its name, there’s nothing cheap about its corporate drama — a ₹600 crore related-party transaction, a Flipkart exit deal, a CFO shuffle, and a subsidiary buyback worth ₹100 crore.

Its FY25 numbers are like a roller coaster designed by a CA who loves chaos:

• Revenue (FY25): ₹1,167 crore
• Operating Margin: -5.61%
• PAT (FY25): ₹-1.16 crore
• ROE: 4.63%
• ROCE: -1.33%
• Debt to Equity: 0.01

In the latest quarter (Q2 FY26), sales grew 10.2% QoQ to ₹301 crore, but PAT fell into the abyss — ₹-12.6 crore, a YoY plunge of -151%. A doctor might say: “the patient is stable, but unconscious.”

2. Introduction

Sastasundar Ventures began life in 1989, way before e-commerce, Flipkart, or “digital health” were even buzzwords. Originally a financial services player, it reinvented itself into a digital healthcare ecosystem — because, in India, every company eventually dreams of being a tech startup.

The grand idea: build a pharma e-commerce platform, add a diagnostic arm, spice it up with wealth management, and serve it as a “core investment company” dish to SEBI. What could go wrong?

In true desi style, the company didn’t stop there. It partnered with Flipkart to launch Flipkart Health+, only to sell its entire stake in 2024. In parallel, its subsidiaries kept fusing, merging, and demerging like bacteria in a lab — Retailer Shakti merged with Healthbuddy, Healthbuddy did a ₹100 crore buyback, and SSVL nodded approvingly from the corner office.

Today, Sastasundar is a strange beast — part fintech, part healthtech, part circus. Its latest results scream “high potential, low patience.” Negative profits, minimal debt, and a balance sheet that looks more like a Sudoku puzzle than a financial statement.

But hey, the promoters keep buying more shares — and when Banwari Lal Mittal buys, the market listens.

3. Business Model – WTF Do They Even Do?

SSVL’s business model is like a buffet where you’re not sure what you’re eating, but you’re definitely full.

It operates through multiple subsidiaries:

• Sastasundar Healthbuddy Ltd (SHBL) – The B2C healthcare arm that ran Flipkart Health+, now busy doing buybacks and battling fraud.
• Retailer Shakti Supply Chain Pvt Ltd – The B2B platform that delivers medicines and FMCG products to pharmacies and kiranas across India.
• Genu Path Labs Ltd – Handles diagnostics, especially in Eastern India, because someone has to actually test the blood while others test investor patience.
• Microsec Wealth Management & Financial Services – The legacy financial arm, offering wealth management, planning, and professional advisory.

The company divides its revenue into two main verticals:

• Healthcare Network (~94%) – Includes SastaSundar, RetailerShakti, and Genu Path Labs.
• Financial Services (~6%) – Loans, securities, and wealth management.

In FY24, the supply chain segment (SastaSundar + RetailerShakti) contributed ~94% of the top line — proof that health and logistics are the lifeblood of this ecosystem.

So yes, they sell medicines online, supply to pharmacies, test your blood, and also help you plan your portfolio. If you ever wondered who’d manage your SIPs and your blood sugar in the same app — this is it.

4. Financials Overview

Commentary:
A 10% jump in sales but a profit collapse. EBITDA swung negative again — the kind of “recovery” that feels like catching a cold after surviving dengue. Net profit fell off a cliff after a brief high last quarter. Clearly, the company needs a CFO who can perform CPR on the P&L statement (oh wait, they just replaced one in February 2025).

5. Valuation Discussion – Fair Value Range

Method 1: P/E Method

• EPS (TTM): ₹-0.64 → P/E not meaningful.
  With losses on the book, valuing SSVL using P/E is like using a thermometer on a rock.

Method 2: EV/EBITDA Method

• EV: ₹996 Cr
• EBITDA (TTM): ₹-25 Cr → EV/EBITDA = -39.8x
  Since EBITDA is negative, again, valuation looks more like satire than math.

Method 3: DCF (Discounted Cash Flow)
Assuming revenue CAGR of 12% (historic 10-year CAGR: 36%), normalized OPM of 5% by FY28, and discount rate of 12% → fair value range ₹260–₹340 per share.

📜 Disclaimer: This fair value range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

• Oct 2024: Sold its entire stake in Flipkart Health Ltd to Flipkart Health Private Ltd, Singapore. Basically, Flipkart took back its health startup; SSVL took the cheque and waved goodbye.